MODIFICATION
A -- SMALLPOX ANTIVIRAL FOR THE STRATEGIC NATIONAL STOCKPILE
- Notice Date
- 12/11/2009
- Notice Type
- Modification/Amendment
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, 330 Independence Avenue, SW, Rm G640, Washington, District of Columbia, 20201, United States
- ZIP Code
- 20201
- Solicitation Number
- RFP-BARDA-09-35
- Archive Date
- 2/26/2010
- Point of Contact
- Michelle T. Gray, Phone: (202) 260-0950, Darrick A Early, Phone: 202-260-0293
- E-Mail Address
-
michelle.gray@hhs.gov, darrick.early@hhs.gov
(michelle.gray@hhs.gov, darrick.early@hhs.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- AMENDED SYNOPSIS (FEDBIZOPPS Notice) - Posted 11 December 2009 Description: This is a formal acknowledgement that additional changes are forthcoming to RFP-BARDA-09-35. This RFP remains a Small Business Set-Aside in accordance with FAR 19.5. The Department of Health and Human Services (HHS), through the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) continue to seek medical countermeasures (MCMs) that will support an effective public health emergency response to smallpox. There will be two significant changes made to the RFP. First, under Section L.5. (Type of Contract and Number of Awards), the United States Government (USG) now contemplates one or more awards of a five-year hybrid Firm Fixed Price/Cost Reimbursable type contract for MCMs that can provide treatment for individuals exposed to smallpox. Second, under Section M.1. (Mandatory Criteria for Eligibility), although the Offeror will still need to provide evidence for therapeutic index in non-human primate model under an eventual contract, the USG is willing to forego this mandatory criterion for eligibility at this time. All other mandatory criteria for eligibility will remain unchanged. It remains imperative that an Offeror(s) responding to this amended RFP seek guidance from the FDA prior to submission of a proposal(s) so the proposal may be aligned with current FDA policy, practices, guidance, and current thinking. All amended details and requirements will be described in the forthcoming amendment to the Smallpox Antiviral solicitation, RFP-BARDA-09-35. This amendment will be made available electronically through www.fbo.gov on or about 28 December 2009. Any responsible Offeror may submit a proposal to be considered by the USG. This amended notice does not commit the USG to the award of a contract(s). Only written or email requests will be accepted directly from the requestor for the solicitation. No collect calls will be accepted. No facsimile transmissions will be accepted. All responses should be identified with the solicitation number RFP-BARDA-09-35, name of company, name of requestor, mailing address, telephone number, fax number, and email address of Point of Contact (POC), should be submitted to the Contracting Officer identified in this notice.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/OOS/OASPHEP/RFP-BARDA-09-35/listing.html)
- Place of Performance
- Address: N/A, United States
- Record
- SN02022614-W 20091213/091211235804-79914e06d0a013ae7714488df881291b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |